KNSA insider sales total $8.34M; 15,091 shares to be sold after option exercise

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 reports an intended sale of 15,091 Class A ordinary shares through Charles Schwab & Co., Inc. for an aggregate market value of $535,778, to be traded on NASDAQ approximately on 09/03/2025. The shares were acquired the same day by an employee stock option exercise and the transaction indicates a broker payment for a cashless exercise.

The filing also discloses insider sales by Eben Tessari during the prior three months totaling 261,881 shares for aggregate gross proceeds of $8,341,479 across seven transactions between 06/09/2025 and 08/18/2025. The filing provides specific trade dates, amounts, and proceeds but does not include additional context or reasons for the sales.

Positive

• Detailed disclosure of share counts, dates, broker and gross proceeds provides regulatory transparency
• Planned sale arises from an employee stock option exercise, and the filing notes a cashless exercise settlement

Negative

• Insider sold 261,881 shares in the prior three months for aggregate gross proceeds of $8,341,479
• Additional planned sale of 15,091 shares worth $535,778 to occur on 09/03/2025 which increases near-term insider supply

Insights

Financial Analyst

TL;DR: Insider sales are disclosed with precise quantities and proceeds; current filing shows a small planned sale after a cashless option exercise.

The filing lists an intended sale of 15,091 shares valued at $535,778 to occur on 09/03/2025 following an employee stock option exercise on the same date settled via broker cashless payment. Recent historical sales by the same insider total 261,881 shares for $8,341,479 between June and August 2025. The disclosure supplies transaction-level detail useful for modeling share count dilution and short-term insider liquidity but contains no operational or financial performance data.

Corporate Governance Expert

TL;DR: Multiple sizable insider sales were executed recently; this raises governance transparency questions though no misconduct is alleged.

The record shows seven insider dispositions over three months and a further planned sale of 15,091 shares following an option exercise. Aggregate recent insider sales amount to 261,881 shares for $8,341,479. From a governance perspective, frequent or sizable insider sales warrant disclosure and monitoring by investors for potential signaling, but the filing itself provides the necessary regulatory transparency without explanatory commentary.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	15091	535778.00	43472928	09/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	09/03/2025	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			15091	09/03/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	06/09/2025	10319	313453.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	06/10/2025	15506	472239.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	06/11/2025	45042	1374277.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	06/16/2025	17300	489171.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	07/14/2025	18900	542860.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	08/05/2025	138614	4602409.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	08/18/2025	16200	547070.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the KNSA Form 144 disclose about the planned sale?

The filing discloses an intended sale of 15,091 Class A ordinary shares via Charles Schwab with an aggregate market value of $535,778, approximately on 09/03/2025 on NASDAQ.

Who conducted insider sales reported in the KNSA filing and how many shares were sold?

The filing lists insider sales by Eben Tessari totaling 261,881 shares across seven transactions from 06/09/2025 to 08/18/2025.

How much did the insider sales raise in gross proceeds according to the filing?

Aggregate gross proceeds from the reported sales equal $8,341,479.

How were the 15,091 shares acquired according to the Form 144?

The 15,091 shares were acquired on 09/03/2025 through an employee stock option exercise and the payment method is listed as broker payment for cashless exercise.

On which exchange will the planned sale of KNSA shares occur?

The planned sale is listed to occur on NASDAQ.